Elicited antibody nature of human monoclonal protein with anti-streptolysin O activity--analysis with monoclonal anti-idiotype antibody.

Abstract	Sera from 7 patients with multiple myeloma having antistreptolysin O (ASO) activity in high titers were detected by a streptolysin O (SLO) inhibition assay. However, activity was in low titer when assayed by a passive agglutination assay. The discrepancy between these 2 assays raised some doubts as to whether these monoclonal proteins (M.protein) bond to SLO in the same manner as elicited antibodies. Immunochemical analysis and idiotope analysis using monoclonal antibody to one of these M.proteins strongly suggest that M.protein with ASO activity bind to SLO in a manner similar to elicited antibody. The discrepancy between the 2 assays might be due to differences in the antigenic structure of different forms of the SLO molecule.
Authors	S Sawada, M Shida, R Suenaga, H Mizuma, M Karasaki, M Hashimoto, K Kawano, I Amaki
Journal	Journal of clinical & laboratory immunology (J Clin Lab Immunol) Vol. 19 Issue 1 Pg. 31-5 (Jan 1986) ISSN: 0141-2760 [Print] Scotland
PMID	2422380 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References	Antibodies Antibodies, Monoclonal Bacterial Proteins Epitopes Immunoglobulin Fab Fragments Immunoglobulin Fc Fragments Immunoglobulin Heavy Chains Immunoglobulin Idiotypes Immunoglobulin Light Chains Immunoglobulins Streptolysins streptolysin O
Topics	Antibodies (immunology) Antibodies, Monoclonal (isolation & purification) Antibody Specificity Bacterial Proteins Cells, Cultured Cross Reactions Epitopes Hemagglutination Tests Humans Hybridomas (classification, immunology) Immunoglobulin Fab Fragments (analysis) Immunoglobulin Fc Fragments (analysis) Immunoglobulin Heavy Chains (analysis) Immunoglobulin Idiotypes (immunology) Immunoglobulin Light Chains (analysis) Immunoglobulins (classification) Multiple Myeloma (immunology) Streptolysins (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!